Tek antagonists

Details Tek antagonists Tek antagonists

2006-06-27

2006-06-27

Spector, Lorraine (Department: 1646)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S350000, C530S387300, C530S402000

Reexamination Certificate

active

07067475

ABSTRACT:
The present invention provides Tek antagonists and methods of inhibiting angiogenesis in a mammal by administering Tek antagonists. The methods are particularly useful in treating diseases or conditions mediated by angiogenesis, such as solid tumors and diseases or conditions characterized by ocular neovascularization.

REFERENCES:
patent: 5447860 (1995-09-01), Ziegler
patent: 5681714 (1997-10-01), Breitman et al.
patent: 5955291 (1999-09-01), Alitalo et al.
patent: 5998187 (1999-12-01), Breitman et al.
patent: 6166185 (2000-12-01), Davis et al.
patent: 6312694 (2001-11-01), Thorpe et al.
patent: 6538103 (2003-03-01), Ji et al.
patent: 854 185 (1998-07-01), None
patent: 06315382 (1994-11-01), None
patent: WO 93 14124 (1993-07-01), None
patent: WO 94 00469 (1994-01-01), None
patent: WO 94/10197 (1994-05-01), None
patent: WO 95 13387 (1995-05-01), None
patent: WO 95 21866 (1995-08-01), None
patent: WO 96 11269 (1996-04-01), None
patent: WO 96 31598 (1996-10-01), None
patent: WO 98 18914 (1998-05-01), None
patent: WO 99/43801 (1999-09-01), None
patent: WO 00/18437 (2000-04-01), None
Denny, T. et al., “Cloning and characterization of tek, the gene encoding the major extracellular protein of pseudomonas solanacearum,”Molecular Plant-Microbe Interactions 9(4):272-281, 1996.
Folkman, J., “Antiangiogenic gene therapy,”Proc. Natl. Acad. Sci USA. 95:9064-9066, 1998.
Hanahan, D., “Signaling vascular morphogenesis and maintenance,”Sci. 277(5322):48-50, 1997.
Koblizek, T. et al., “Tie2 receptor expression and phosphorylation in cultured cells and mouse tissues,”Eur. J. Biochem. 244:774-779, 1997.
Labrador, J. et al., The N-terminal globular domain of Eph receptor is sufficient for ligand binding and receptor signaling.EMBO J. 16(13): 3889-3897, 1997.
Lackmann, M. et al., Distinct subdomains of the EphA3 receptor mediate ligand binding and receptor dimerization.J.Biol.Chem. 273(32); 20228-20237, 1998.
Lin, P. et al., “Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2,”Proc. Natl. Acad. Sci USA. 95:8829-8834, 1998.
Lin, P. et al., “Inhibition of tumor angiogenesis using a soluble receptor establishes a role for Tie2 in pathologic vascular growth,”J. Clin. Invest. 100(8); 2072-2078, 1997.
Peters, K. et al., “Expression of Tie2/Tek in breast tumour vasculature provides a new marker for evaluation of tumour angiogenesis,”British J. Cancer 77(1):51-56, 1998.

Affiliated with

Also associated with

Rating

Tek antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Tek antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tek antagonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3617987